Identification of diabetic nephropathy-selective proteins in human plasma by multi-lectin affinity chromatography and LC-MS/MS

Proteomics - Clinical Applications

Volumn 4, Issue 6-7, 2010, Pages 644-653

  Ahn, Jung Mo ^a   Kim, Byung Gyu ^a   Yu, Myong Hee ^b   Lee, In Kyu ^c   Cho, Je Yoel ^a  

^a Kyungpook National University   (South Korea)

^b Korea Institute of Science and Technology   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

Author keywords

Diabetic nephropathy; Glycoprotein; Human plasma; Multi lectin affinity column

Indexed keywords

GLYCOPROTEIN; LECTIN; LUMICAN; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG; VASORIN;

ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE MARKER; DOWN REGULATION; HUMAN; KIDNEY INJURY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN ISOLATION; PROTEIN URINE LEVEL; PROTEOMICS; QUANTITATIVE STUDY; UPREGULATION; WESTERN BLOTTING;

BIOLOGICAL MARKERS; CARRIER PROTEINS; CHONDROITIN SULFATE PROTEOGLYCANS; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; GLYCOPROTEINS; HUMANS; KERATAN SULFATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RETINOL-BINDING PROTEINS, PLASMA; TANDEM MASS SPECTROMETRY;

EID: 77955826148     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.200900196     Document Type: Article

References (34)

1. Ritz, E., Diabetic nephropathy. Saudi J. Kidney Dis. Transpl. 2006, 17, 481-490.
2. Parving, H. H., Diabetic nephropathy: prevention and treatment. Kidney Int. 2001, 60, 2041-2055.
3. Otu, H. H., Can, H., Spentzos, D., Nelson, R. G., et al., Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007, 30, 638-643.
4. Remuzzi, G., Schieppati, A., Ruggenenti, P., Clinical practice. Nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2002, 346, 1145-1151.
5. Jain, S., Rajput, A., Kumar, Y., Uppuluri, N., et al., Proteomic analysis of urinary protein markers for accurate prediction of diabetic kidney disorder. J. Assoc. Physicians India 2005, 53, 513-520.
6. Kim, H. J., Cho, E. H., Yoo, J. H., Kim, P. K., et al., Proteome analysis of serum from type 2 diabetics with nephropathy. J. Proteome Res. 2007, 6, 735-743.
7. Mischak, H., Kaiser, T., Walden, M., Hillmann, M., et al., Proteomic analysis for the assessment of diabetic renal damage in humans. Clin. Sci. (Lond). 2004, 107, 485-495.
8. Rao, P. V., Lu, X., Standley, M., Pattee, P., et al., Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care 2007, 30, 629-637.
9. Merchant, M. L., Klein, J. B., Proteomics and diabetic nephropathy. Curr. Diab. Rep. 2005, 5, 464-469.
10. Thongboonkerd, V., Barati, M. T., McLeish, K. R., Pierce, W. M., et al., Proteomics and diabetic nephropathy. Contrib. Nephrol. 2004, 141, 142-154.
11. Thongboonkerd, V., Barati, M. T., McLeish, K. R., Benarafa, C., et al., Alterations in the renal elastin-elastase system in type 1 diabetic nephropathy identified by proteomic analysis. J. Am. Soc. Nephrol. 2004, 15, 650-662.
12. Helenius, A., Aebi, M., Intracellular functions of N-linked glycans. Science 2001, 291, 2364-2369.
13. Lowe, J. B., Glycosylation, immunity, and autoimmunity. Cell 2001, 104, 809-812.
14. Heo, S. H., Lee, S. J., Ryoo, H. M., Park, J. Y., Cho, J. Y., Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/MS. Proteomics 2007, 7, 4292-4302.
15. Sun, B., Ranish, J. A., Utleg, A. G., White, J. T., et al., Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics. Mol. Cell Proteomics 2007, 6, 141-149.
16. Koschinsky, T., He, C. J., Mitsuhashi, T., Bucala, R., et al., Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc. Natl. Acad. Sci. USA 1997, 94, 6474-6479.
17. Kassiri, Z., Oudit, G. Y., Kandalam, V., Awad, A., et al., Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 2009, 20, 1223-1235.
18. Keller, A., Nesvizhskii, A. I., Kolker, E., Aebersold, R., Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74, 5383-5392.
19. Nesvizhskii, A. I., Keller, A., Kolker, E., Aebersold, R., A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75, 4646-4658.
20. Hendrickson, E. L., Xia, Q., Wang, T., Leigh, J. A., Hackett, M., Comparison of spectral counting and metabolic stable isotope labeling for use with quantitative microbial proteomics. The Analyst 2006, 131, 1335-1341.
21. Yang, Y. H., Zhang, S., Cui, J. F., Lu, B., et al., Diagnostic potential of serum protein pattern in Type 2 diabetic nephropathy. Diabet. Med. 2007, 24, 1386-1392.
22. Rossing, P., Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006, 49, 11-19.
23. Graves, D. T., Kayal, R. A., Diabetic complications and dysregulated innate immunity. Front. Biosci. 2008, 13, 1227-1239.
24. Knight, S. F., Imig, J. D., Obesity, insulin resistance, and renal function. Microcirculation 2007, 14, 349-362.
25. Murata,M., Saito, T., Otani, T., Sasaki,M., et al., An increase in serum retinol-binding protein 4 in the type 2 diabetic subjects with nephropathy. Endocrine J. 2009, 56, 287-294.
26. Raila, J., Henze, A., Spranger, J., Mohlig, M., et al., Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int. 2007, 72, 505-511.
27. Lu, G. Y., Shen, L., Wang, Z. Y., Guo, X. F., et al., Significance of plasma von Willebrand factor level and von Willebrand factor-cleaving protease activity in patients with chronic renal diseases. Chin. Med. J. (England). 2008, 121, 133-136.
28. Chakravarti, S., Magnuson, T., Lass, J. H., Jepsen, K. J., et al., Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J. Cell Biol. 1998, 141, 1277-1286.
29. Svensson, L., Aszodi, A., Reinholt, F. P., Fassler, R., et al., Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J. Biol. Chem. 1999, 274, 9636-9647.
30. Metz, T. O., Qian, W. J., Jacobs, J. M., Gritsenko, M. A., et al., Application of proteomics in the discovery of candidate protein biomarkers in a diabetes autoantibody standardization program sample subset. J. Proteome Res. 2008, 7, 698-707.
31. Schaefer, L., Raslik, I., Grone, H. J., Schonherr, E., et al., Small proteoglycans in human diabetic nephropathy: discrepancy between glomerular expression and protein accumulation of decorin, biglycan, lumican, and fibromodulin. FASEB J. 2001, 15, 559-561.
32. Ikeda, Y., Imai, Y., Kumagai, H., Nosaka, T., et al., Vasorin, a transforming growth factor beta-binding protein expressed in vascular smooth muscle cells, modulates the arterial response to injury in vivo. Proc. Natl. Acad. Sci. USA 2004, 101, 10732-10737.
33. Chan, A. K., Rak, J., Berry, L., Liao, P., et al., Antithrombinheparin covalent complex: a possible alternative to heparin for arterial thrombosis prevention. Circulation 2002, 106, 261-265.
34. Weitz, J. I., Young, E., Johnston, M., Stafford, A. R., et al., Vasoflux, a new anticoagulant with a novel mechanism of action. Circulation 1999, 99, 682-689.